Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic Precursor Cell Enumeration with First-Harvest CD34+ Stem Cell Yield

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 12, 2012, Pages 1867-1875

  Villa, Carlos H ^a   Shore, Tsiporah ^b   Van Besien, Koen ^b   Cushing, Melissa ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hematology analyzer; Stem cell collection

Indexed keywords

CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PLERIXAFOR; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CELL COUNT; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PREDICTION; PREDICTIVE VALUE; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION;

ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84869091734     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.07.002     Document Type: Article

References (25)

1. Harousseau J.L., Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009, 360:2645-2654.
2. Cutler C., Antin J.H. Peripheral blood stem cells for allogeneic transplantation: a review. Stem Cells 2001, 19:108-117.
3. Sinha S., Gastineau D., Micallef I., et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011, 46:943-949.
4. Brissot E., Chevallier P., Guillaume T., et al. Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors. Bone Marrow Transplant 2009, 44:613-615.
5. Bensinger W., DiPersio J.F., McCarty J.M. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009, 43:181-195.
6. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003, 2:581-587.
7. Keating G.M. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs 2011, 71:1623-1647.
8. Kessans M.R., Gatesman M.L., Kockler D.R. Plerixafor: a peripheral blood stem cell mobilizer. Pharmacotherapy 2010, 30:485-492.
9. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004, 22:1095-1102.
10. Mohty M., Ho A.D. In and out of the niche: perspectives in mobilization of hematopoietic stem cells. Exp Hematol 2011, 39:723-729.
11. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
12. Zeng Z., Shi Y.X., Samudio I.J., et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113:6215-6224.
13. Allan D.S., Keeney M., Howson-Jan K., et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 29:967-972.
14. Vaughan W., Seshadri T., Bridges M., et al. The principles and overview of autologous hematopoietic stem cell transplantation. Cancer Treat Res 2009, 144:23-45.
15. Siena S., Schiavo R., Pedrazzoli P., et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000, 18:1360-1377.
16. Sezer O., Possinger K., Metzner B., et al. Optimal CD34(+) cell dose in autologous peripheral-blood stem-cell transplantation. J Clin Oncol 2000, 18:3319-3320.
17. + cell yield in the leukapheresis product. Cytotherapy 1999, 1:141-146.
18. Armitage S., Hargreaves R., Samson D., et al. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant 1997, 20:587-591.
19. + cell yield in the apheresis collection. Bone Marrow Transplant 2000, 25:1157-1164.
20. Takekawa K., Yamane T., Hino M., et al. Determination of hematopoietic stem cells in peripheral blood by an automated hematology analyzer (SE-9000). Acta Haematol 1998, 100:130-136.
21. + cell concentrations to optimize peripheral blood progenitor cell collection by apheresis. Transfusion 2007, 47:1851-1857.
22. Pollard Y., Watts M.J., Grant D., et al. Use of the haemopoietic progenitor cell count of the Sysmex SE-9500 to refine apheresis timing of peripheral blood stem cells. Br J Haematol 1999, 106:538-544.
23. + cell yields in granulocyte colony-stimulating factor-mobilized peripheral blood stem cell harvest in healthy donors. Transfusion 2010, 50:1088-1095.
24. Zakaryan A., Karageuzyan K., Hovsepyan L., et al. Quantitative analysis of phospholipids and gangliosides in bone marrow progenitors of lymphocytes, thymocytes and mature lymphocytes in tumor-bearing animals. Int Immunol 2001, 13:1141-1145.
25. Kraai R., Reymer A.G., Brouwer-Mandema G.G., et al. Hemopoietic stem and precursor cell analysis in umbilical cord blood using the Sysmex SE-9000 IMI. Cytometry 2001, 46:114-118.